Compare VVX & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVX | NKTR |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2014 | 1996 |
| Metric | VVX | NKTR |
|---|---|---|
| Price | $79.47 | $74.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $69.88 | ★ $146.67 |
| AVG Volume (30 Days) | ★ 673.0K | 601.3K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 126.85 | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $4,480,038,000.00 | $307,711,000.00 |
| Revenue This Year | $7.81 | N/A |
| Revenue Next Year | $5.84 | N/A |
| P/E Ratio | $58.52 | ★ N/A |
| Revenue Growth | 3.65 | ★ 86.00 |
| 52 Week Low | $50.89 | $26.45 |
| 52 Week High | $93.98 | $109.00 |
| Indicator | VVX | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 55.84 |
| Support Level | $65.02 | $64.99 |
| Resistance Level | $92.89 | $76.45 |
| Average True Range (ATR) | 4.00 | 2.80 |
| MACD | -0.49 | -0.09 |
| Stochastic Oscillator | 20.62 | 73.00 |
V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.